Alkermes Rallies as FDA Accepts NDA for Depression Drug

Shares of Alkermes plc  ALKSjumped about 4.5% when the FDA accepted for review the new drug application (NDA) for ALKS 5461 for the treatment of major depressive disorder (“MDD”). The FDA had initially issued a Refusal to File letter on Mar 30 for the candidate stating that the NDA did not have enough evidence for the oral medication to work.